Clinical Trials Logo

HER2-positive Bladder Cancer clinical trials

View clinical trials related to HER2-positive Bladder Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT03650348 Completed - Clinical trials for HER2-positive Breast Cancer

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

Start date: August 21, 2018
Phase: Phase 1
Study type: Interventional

A Phase 1b, open-label, dose escalation study of PRS-343 in combination with atezolizumab in patients with HER2-positive advanced or metastatic solid tumors.

NCT ID: NCT03330561 Completed - Clinical trials for HER2-positive Breast Cancer

PRS-343 in HER2-Positive Solid Tumors

Start date: September 13, 2017
Phase: Phase 1
Study type: Interventional

A multi center, open-label, Phase 1 dose escalation study with expansion cohort is designed to determine the MTD, RP2D and dosing schedule of PRS-343 in patients with HER2+ advanced or metastatic solid tumors.